1. Home
  2. TVTX vs CNS Comparison

TVTX vs CNS Comparison

Compare TVTX & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$28.06

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$68.13

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
CNS
Founded
N/A
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.2B
IPO Year
2013
2004

Fundamental Metrics

Financial Performance
Metric
TVTX
CNS
Price
$28.06
$68.13
Analyst Decision
Strong Buy
Hold
Analyst Count
14
2
Target Price
$36.85
$72.50
AVG Volume (30 Days)
1.3M
243.4K
Earning Date
05-11-2026
04-23-2026
Dividend Yield
N/A
3.95%
EPS Growth
92.89
N/A
EPS
N/A
2.97
Revenue
N/A
$427,536,000.00
Revenue This Year
$44.75
$7.83
Revenue Next Year
$26.82
$11.02
P/E Ratio
N/A
$22.87
Revenue Growth
N/A
4.07
52 Week Low
$12.91
$58.39
52 Week High
$42.13
$88.49

Technical Indicators

Market Signals
Indicator
TVTX
CNS
Relative Strength Index (RSI) 40.24 57.70
Support Level $27.01 $63.76
Resistance Level $31.47 $68.30
Average True Range (ATR) 1.64 2.17
MACD -0.02 0.22
Stochastic Oscillator 25.89 78.22

Price Performance

Historical Comparison
TVTX
CNS

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.

Share on Social Networks: